||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (June 2010)|
|Systematic (IUPAC) name|
|Half-life||3 to 9 hours|
|(what is this?)|
Ethotoin (marketed as Peganone by Ovation) is an anticonvulsant drug used in the treatment of epilepsy. It is a hydantoin, similar to phenytoin. Ethotoin lacks phenytoin's side effects of gingival hyperplasia and hirsutism, however it is less effective. This, combined with the need for frequent dosing has limited its usefulness. Ethotoin is no longer widely used.
Mechanism of action
Similar to phenytoin.
- 1957 Peganone was granted Food and Drug Administration (FDA) approval to Abbott Laboratories for treatment of grand mal (tonic clonic) and partial complex (psychomotor) seizures.
- 2003 Peganone was acquired from Abbott Laboratories by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).
Indications and usage
Ethotoin is indicated for tonic-clonic and partial complex seizures.
Ethotoin is available in 250mg tablets. It is taken orally in 4 to 6 divided doses per day, preferably after food.
Ethotoin, 3-ethyl-5-phenylimidazolidine-2,4-dione, is synthesized by the reaction of benzaldehyde oxynitrile, with urea or ammonium hydrocarbonate, which forms an intermediate urea derivative which on acidic conditions cyclizes to 5-phenylhydantoin. Alkylation of this product using ethyliodide leads to the formation of ethotoin.
- A. Pinner, Chem. Ber., 21, 2324 (1888).
- W.J. Close, U.S. Patent 2,793,157 (1946).
- Schwade ED, Richards RK, Everett GM (May 1956). "Peganone, a new antiepileptic drug". Dis Nerv Syst 17 (5): 155–8. PMID 13317788.
- Shorvon, S.D.; Fish, David R.; Perucca, Emilio; Dodson, W. Edwin, ed. (2004). The Treatment of Epilepsy. Blackwell Publishing. ISBN 0-632-06046-8.
- Drugs.com: Ethotoin
- PEGANONE 250 mg Ethotoin Tablets, USP (PDF)